GSK plc GLAXF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 44.55B | 43.93B | 43.12B | 42.05B | 40.96B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.55B | 43.93B | 43.12B | 42.05B | 40.96B |
| Cost of Revenue | 11.80B | 11.92B | 11.82B | 11.59B | 11.60B |
| Gross Profit | 32.75B | 32.02B | 31.30B | 30.47B | 29.36B |
| SG&A Expenses | 12.21B | 12.12B | 11.89B | 11.71B | 13.69B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2.37B | -2.42B | -1.81B | -1.08B | -638.86M |
| Total Operating Expenses | 31.01B | 30.68B | 30.69B | 30.51B | 32.70B |
| Operating Income | 13.55B | 13.25B | 12.43B | 11.54B | 8.26B |
| Income Before Tax | 7.94B | 9.98B | 9.75B | 9.21B | 5.98B |
| Income Tax Expenses | 861.06M | 1.45B | 1.46B | 1.25B | 823.22M |
| Earnings from Continuing Operations | 7.08K | 8.53K | 8.29K | 7.96K | 5.16K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -593.50M | -706.26M | -755.24M | -745.63M | -729.05M |
| Net Income | 6.48B | 7.83B | 7.53B | 7.22B | 4.43B |
| EBIT | 13.55B | 13.25B | 12.43B | 11.54B | 8.26B |
| EBITDA | 16.87B | 17.10B | 16.70B | 15.49B | 12.44B |
| EPS Basic | 1.61 | 1.94 | 1.86 | 1.78 | 1.09 |
| Normalized Basic EPS | 1.84 | 1.76 | 1.62 | 1.49 | 0.99 |
| EPS Diluted | 1.59 | 1.91 | 1.83 | 1.75 | 1.07 |
| Normalized Diluted EPS | 1.81 | 1.73 | 1.60 | 1.47 | 0.97 |
| Average Basic Shares Outstanding | 16.09B | 16.14B | 16.20B | 16.27B | 16.31B |
| Average Diluted Shares Outstanding | 16.32B | 16.37B | 16.44B | 16.49B | 16.53B |
| Dividend Per Share | 0.91 | 0.90 | 0.87 | 0.84 | 0.82 |
| Payout Ratio | 55.18% | 44.43% | 44.90% | 45.82% | 72.89% |